Cargando…

Systematic literature review of immunoglobulin trends for anti-CD20 monoclonal antibodies in multiple sclerosis

OBJECTIVE: To exp lore changes in immunoglobulin (Ig) levels for people with relapsing-multiple sclerosis (RMS) treated with ocrelizumab or ofatumumab and the relationship between Ig levels and infections. METHODS: A systematic literature review (SLR) was conducted to identify clinical trials and re...

Descripción completa

Detalles Bibliográficos
Autores principales: Saidha, Shiv, Bell, Judith, Harold, Sydney, Belisario, Jose Marcano, Hawe, Emma, Shao, Qiujun, Wyse, Kerri, Maiese, Eric M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843103/
https://www.ncbi.nlm.nih.gov/pubmed/36648561
http://dx.doi.org/10.1007/s10072-022-06582-y
_version_ 1784870309786025984
author Saidha, Shiv
Bell, Judith
Harold, Sydney
Belisario, Jose Marcano
Hawe, Emma
Shao, Qiujun
Wyse, Kerri
Maiese, Eric M.
author_facet Saidha, Shiv
Bell, Judith
Harold, Sydney
Belisario, Jose Marcano
Hawe, Emma
Shao, Qiujun
Wyse, Kerri
Maiese, Eric M.
author_sort Saidha, Shiv
collection PubMed
description OBJECTIVE: To exp lore changes in immunoglobulin (Ig) levels for people with relapsing-multiple sclerosis (RMS) treated with ocrelizumab or ofatumumab and the relationship between Ig levels and infections. METHODS: A systematic literature review (SLR) was conducted to identify clinical trials and real-world evidence (RWE) studies on Ig levels over time and studies on associations with infections for ocrelizumab and ofatumumab for people with RMS through 10 September 2021. Searches were conducted in Embase, MEDLINE, Cochrane Library, trial registries, and recent conference abstracts. RESULTS: Of 1,580 articles identified, 30 reporting on 11 trials and 5 RWE studies were included. Ocrelizumab trials (n = 4) had 24–336 weeks of follow-up and reported decreasing Ig G (IgG) levels, while RWE (n = 5) had 52–78 weeks of follow-up and reported IgG to be stable or decrease only slightly. IgG levels were stable in ofatumumab trials (n = 5; 104–168 weeks of follow-up), but no RWE or longer-term studies were identified. No apparent association between decreased Ig levels and infections was observed during ofatumumab treatment (ASCLEPIOS I/II), while for ocrelizumab, the only data on apparent associations between decreased IgG levels and serious infection rates were for a pooled population of people with RMS or primary progressive MS. CONCLUSION: Decreasing IgG levels have been correlated with increased infection risk over time. IgG levels appeared to decrease over time in ocrelizumab trials but remained relatively stable over time in ofatumumab trials. Additional research is needed to understand differences between ocrelizumab and ofatumumab and identify people at risk of decreasing IgG levels and infection. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10072-022-06582-y.
format Online
Article
Text
id pubmed-9843103
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-98431032023-01-17 Systematic literature review of immunoglobulin trends for anti-CD20 monoclonal antibodies in multiple sclerosis Saidha, Shiv Bell, Judith Harold, Sydney Belisario, Jose Marcano Hawe, Emma Shao, Qiujun Wyse, Kerri Maiese, Eric M. Neurol Sci Review Article OBJECTIVE: To exp lore changes in immunoglobulin (Ig) levels for people with relapsing-multiple sclerosis (RMS) treated with ocrelizumab or ofatumumab and the relationship between Ig levels and infections. METHODS: A systematic literature review (SLR) was conducted to identify clinical trials and real-world evidence (RWE) studies on Ig levels over time and studies on associations with infections for ocrelizumab and ofatumumab for people with RMS through 10 September 2021. Searches were conducted in Embase, MEDLINE, Cochrane Library, trial registries, and recent conference abstracts. RESULTS: Of 1,580 articles identified, 30 reporting on 11 trials and 5 RWE studies were included. Ocrelizumab trials (n = 4) had 24–336 weeks of follow-up and reported decreasing Ig G (IgG) levels, while RWE (n = 5) had 52–78 weeks of follow-up and reported IgG to be stable or decrease only slightly. IgG levels were stable in ofatumumab trials (n = 5; 104–168 weeks of follow-up), but no RWE or longer-term studies were identified. No apparent association between decreased Ig levels and infections was observed during ofatumumab treatment (ASCLEPIOS I/II), while for ocrelizumab, the only data on apparent associations between decreased IgG levels and serious infection rates were for a pooled population of people with RMS or primary progressive MS. CONCLUSION: Decreasing IgG levels have been correlated with increased infection risk over time. IgG levels appeared to decrease over time in ocrelizumab trials but remained relatively stable over time in ofatumumab trials. Additional research is needed to understand differences between ocrelizumab and ofatumumab and identify people at risk of decreasing IgG levels and infection. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10072-022-06582-y. Springer International Publishing 2023-01-17 2023 /pmc/articles/PMC9843103/ /pubmed/36648561 http://dx.doi.org/10.1007/s10072-022-06582-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Review Article
Saidha, Shiv
Bell, Judith
Harold, Sydney
Belisario, Jose Marcano
Hawe, Emma
Shao, Qiujun
Wyse, Kerri
Maiese, Eric M.
Systematic literature review of immunoglobulin trends for anti-CD20 monoclonal antibodies in multiple sclerosis
title Systematic literature review of immunoglobulin trends for anti-CD20 monoclonal antibodies in multiple sclerosis
title_full Systematic literature review of immunoglobulin trends for anti-CD20 monoclonal antibodies in multiple sclerosis
title_fullStr Systematic literature review of immunoglobulin trends for anti-CD20 monoclonal antibodies in multiple sclerosis
title_full_unstemmed Systematic literature review of immunoglobulin trends for anti-CD20 monoclonal antibodies in multiple sclerosis
title_short Systematic literature review of immunoglobulin trends for anti-CD20 monoclonal antibodies in multiple sclerosis
title_sort systematic literature review of immunoglobulin trends for anti-cd20 monoclonal antibodies in multiple sclerosis
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843103/
https://www.ncbi.nlm.nih.gov/pubmed/36648561
http://dx.doi.org/10.1007/s10072-022-06582-y
work_keys_str_mv AT saidhashiv systematicliteraturereviewofimmunoglobulintrendsforanticd20monoclonalantibodiesinmultiplesclerosis
AT belljudith systematicliteraturereviewofimmunoglobulintrendsforanticd20monoclonalantibodiesinmultiplesclerosis
AT haroldsydney systematicliteraturereviewofimmunoglobulintrendsforanticd20monoclonalantibodiesinmultiplesclerosis
AT belisariojosemarcano systematicliteraturereviewofimmunoglobulintrendsforanticd20monoclonalantibodiesinmultiplesclerosis
AT haweemma systematicliteraturereviewofimmunoglobulintrendsforanticd20monoclonalantibodiesinmultiplesclerosis
AT shaoqiujun systematicliteraturereviewofimmunoglobulintrendsforanticd20monoclonalantibodiesinmultiplesclerosis
AT wysekerri systematicliteraturereviewofimmunoglobulintrendsforanticd20monoclonalantibodiesinmultiplesclerosis
AT maieseericm systematicliteraturereviewofimmunoglobulintrendsforanticd20monoclonalantibodiesinmultiplesclerosis